Core Insights - Taihe Cheng Medical (CCM) experienced an intraday increase of 8.43%, reaching a price of $5.4 per share, with a total market capitalization of $26.79 million [1] - As of December 31, 2024, the company's total revenue is projected to be 384 million RMB, reflecting a year-on-year decrease of 28.55%, while the net profit attributable to shareholders is expected to be -30.8 million RMB, a decline of 3.56% year-on-year [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, aiming to collaborate on diagnostic technology, radiation quality control, medical processes, operational management, brand usage in Singapore and mainland China, and the operation and training of proton centers [1] - The partnership focuses on building an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research orientation, enhancing patient experience and improving cancer treatment standards in China [1]